{"id":2451,"date":"2017-12-07T17:34:17","date_gmt":"2017-12-07T12:04:17","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2451"},"modified":"2021-07-24T12:56:53","modified_gmt":"2021-07-24T07:26:53","slug":"business-cocktail-15","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-15","title":{"rendered":"December 7 Business Cocktail"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a094c6a288f9\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a094c6a288f9\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-15\/#AbbVie_aims_for_best-in-class_psoriasis_prospect\" >AbbVie aims for best-in-class psoriasis prospect<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-15\/#Amid_US_market_decline_Novartis_looks_at_offloading_its_generic_pills_business\" >Amid US market decline, Novartis looks at offloading its generic pills business<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-15\/#J_J_Bayer_lose_first_Xarelto_case_hit_with_28M_verdict\" >J&amp;J, Bayer lose first Xarelto case, hit with $28M verdict<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-15\/#Depomed_sells_off_Nucynta_and_cuts_40_workforce_to_reduce_costs\" >Depomed sells off Nucynta, and cuts 40% workforce to reduce costs<\/a><\/li><\/ul><\/nav><\/div>\n<h3><span class=\"ez-toc-section\" id=\"AbbVie_aims_for_best-in-class_psoriasis_prospect\"><\/span>AbbVie aims for best-in-class psoriasis prospect<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The last few years have seen a wave of new biologics take the psoriasis market by storm. But a best-in-class product may still be on its way. AbbVie prospect risankizumab showed it could bring 47% of patients to complete skin clearance by week 16 of treatment in a phase 3 study, topping placebo, which hit that benchmark in just 1% of patients. And of those who did achieve clear or almost clear skin, 87% were still in that group at the one-year mark. The AbbVie wannabe produced a slightly higher proportion of patients hitting key benchmarks on the skin-clearance scale, and with less-frequent dosing than the J&amp;J product, Tremfya. if risankizumab can really pass Tremfya to become the \u201cpreferred\u201d med in its class, sales forecast predict $1.2 billion in risk-adjusted peak sales for 2026, with just in the psoriasis indication alone.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Amid_US_market_decline_Novartis_looks_at_offloading_its_generic_pills_business\"><\/span>Amid US market decline, Novartis looks at offloading its generic pills business<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The market for generic pills has gotten so bad in the U.S. that Novartis is thinking about selling off its oral solids business there, outgoing CEO Joseph Jimenez has told analysts. The question of whether the Swiss drugmaker would ever spin off its Sandoz generics business came up during a conversation that Bernstein analysts had last week with Jimenez and drug development chief Vas Narasimhan. Novartis still likes the generics business outside the U.S., where he said biosimilars have given Sandoz a leading position, but it is thinking about exiting the oral solids portion of this business in the U.S. as that market continues to deteriorate. Given that the price erosion looks to continue for some time, Sandoz is concentrating on biosimilars and complex generics, where product differentiation can provide some pricing leverage.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"J_J_Bayer_lose_first_Xarelto_case_hit_with_28M_verdict\"><\/span>J&amp;J, Bayer lose first Xarelto case, hit with $28M verdict<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>After three wins in cases over the risks of blockbuster blood thinner Xarelto, Bayer and Johnson &amp; Johnson have encountered their first defeat. A jury in Philadelphia ordered the drugmakers to pay $28 million to plaintiff Lynn Hartman, but the companies plan to appeal. But J&amp;J and Bayer contend that Xarelto&#8217;s label does disclose its risks. The company faces thousands more liability cases, 21,400 in fact, according to J&amp;J&#8217;s most recent quarterly filing. About 1,400 are pending in Philadelphia. First approved by the FDA in 2011, Xarelto was Bayer\u2019s top-selling drug last year at $3.24 billion and ranked third for J&amp;J at $2.5 billion in sales.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Depomed_sells_off_Nucynta_and_cuts_40_workforce_to_reduce_costs\"><\/span>Depomed sells off Nucynta, and cuts 40% workforce to reduce costs<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Depomed is selling off the franchise that was once the center of its growth hopes, and plenty of the company&#8217;s employees are leaving with it. Less than three years after shelling out $1.05 billion to acquire Nucynta ER and XR from Johnson &amp; Johnson, the California drugmaker has licensed the meds to Collegium Pharmaceutical for just $10 million upfront. For the first four years of the pact, Depomed will receive a minimum of $135 million in royalties each year, and after that, that minimum will disappear. The switch will also save the company some cash, though: It\u2019s slashing its pain salesforce and all brand spending on the franchise, taking SG&amp;A costs down by $70 million each year. The transaction will also \u2018improve\u2019 Depomed\u2019s 2018 earnings outlook, it said, though \u2018details are unclear\u2019.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AbbVie aims for best-in-class psoriasis prospect The last few years have seen a wave of new biologics take the psoriasis market by storm. But a best-in-class product may still be on its way. AbbVie prospect risankizumab showed it could bring 47% of patients to complete skin clearance by week 16 of treatment in a phase [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2290,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[56,107,776,134,1155,204,17606,1231,1055,423,17605,1230,712,909,1232,639,1204,5587,1985],"industry":[17225],"therapeutic_areas":[17242,17227,17278],"class_list":["post-2451","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-abbvie","tag-bayer","tag-business-cocktail","tag-business-consultant","tag-consultancy","tag-delveinsight","tag-depomed","tag-industry-news","tag-latest-pharma","tag-novartis","tag-nucynta","tag-pharma-consultancy","tag-pharma-industry","tag-pharma-industry-news","tag-pharma-latest-news","tag-pharma-news","tag-pharma-reports","tag-psoriasis","tag-xarelto","industry-pharmaceutical","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-other-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>December 7 Business Cocktail - DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"AbbVie prospect risankizumab showed it could bring 47% of patients to complete skin clearance by week 16 of treatment in a phase 3 study, topping placebo...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-15\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"December 7 Business Cocktail - DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"AbbVie prospect risankizumab showed it could bring 47% of patients to complete skin clearance by week 16 of treatment in a phase 3 study, topping placebo...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-15\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-12-07T12:04:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021353\/pharma-licensing.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"620\" \/>\n\t<meta property=\"og:image:height\" content=\"414\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"December 7 Business Cocktail - DelveInsight Business Research","description":"AbbVie prospect risankizumab showed it could bring 47% of patients to complete skin clearance by week 16 of treatment in a phase 3 study, topping placebo...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-15","og_locale":"en_US","og_type":"article","og_title":"December 7 Business Cocktail - DelveInsight Business Research","og_description":"AbbVie prospect risankizumab showed it could bring 47% of patients to complete skin clearance by week 16 of treatment in a phase 3 study, topping placebo...","og_url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-15","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-12-07T12:04:17+00:00","article_modified_time":"2021-07-24T07:26:53+00:00","og_image":[{"width":620,"height":414,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021353\/pharma-licensing.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-15","url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-15","name":"December 7 Business Cocktail - DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-15#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-15#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021353\/pharma-licensing.jpg","datePublished":"2017-12-07T12:04:17+00:00","dateModified":"2021-07-24T07:26:53+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"AbbVie prospect risankizumab showed it could bring 47% of patients to complete skin clearance by week 16 of treatment in a phase 3 study, topping placebo...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/business-cocktail-15"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-15#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021353\/pharma-licensing.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021353\/pharma-licensing.jpg","width":620,"height":414,"caption":"Entasis"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021353\/pharma-licensing-300x200.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AbbVie<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bayer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Business Cocktail<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Business Consultant<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">consultancy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Depomed<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">industry news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">latest pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novartis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Nucynta<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma consultancy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pharma Industry<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pharma Industry News<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma latest news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma reports<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Psoriasis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Xarelto<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AbbVie<\/span>","<span class=\"advgb-post-tax-term\">Bayer<\/span>","<span class=\"advgb-post-tax-term\">Business Cocktail<\/span>","<span class=\"advgb-post-tax-term\">Business Consultant<\/span>","<span class=\"advgb-post-tax-term\">consultancy<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Depomed<\/span>","<span class=\"advgb-post-tax-term\">industry news<\/span>","<span class=\"advgb-post-tax-term\">latest pharma<\/span>","<span class=\"advgb-post-tax-term\">Novartis<\/span>","<span class=\"advgb-post-tax-term\">Nucynta<\/span>","<span class=\"advgb-post-tax-term\">pharma consultancy<\/span>","<span class=\"advgb-post-tax-term\">Pharma Industry<\/span>","<span class=\"advgb-post-tax-term\">Pharma Industry News<\/span>","<span class=\"advgb-post-tax-term\">pharma latest news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">pharma reports<\/span>","<span class=\"advgb-post-tax-term\">Psoriasis<\/span>","<span class=\"advgb-post-tax-term\">Xarelto<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Dec 7, 2017","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Dec 7, 2017 5:34 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2451","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2451"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2451\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2290"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2451"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2451"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2451"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2451"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2451"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}